2P4 Stock Overview
An in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
BioPorto A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 0.21 |
| 52 Week High | DKK 0.43 |
| 52 Week Low | DKK 0.15 |
| Beta | 1.15 |
| 11 Month Change | -6.58% |
| 3 Month Change | -23.93% |
| 1 Year Change | -29.35% |
| 33 Year Change | -44.60% |
| 5 Year Change | -43.95% |
| Change since IPO | -49.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2P4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.1% | -0.02% | -1.5% |
| 1Y | -29.4% | -17.7% | 7.9% |
Return vs Industry: 2P4 underperformed the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: 2P4 underperformed the German Market which returned 8.3% over the past year.
Price Volatility
| 2P4 volatility | |
|---|---|
| 2P4 Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2P4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2P4's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 27 | Peter Eriksen | bioporto.com |
BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was incorporated in 1917 and is based in Hellerup, Denmark.
BioPorto A/S Fundamentals Summary
| 2P4 fundamental statistics | |
|---|---|
| Market cap | €93.43m |
| Earnings (TTM) | -€6.70m |
| Revenue (TTM) | €4.54m |
20.6x
P/S Ratio-13.9x
P/E RatioIs 2P4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2P4 income statement (TTM) | |
|---|---|
| Revenue | DKK 33.83m |
| Cost of Revenue | DKK 9.55m |
| Gross Profit | DKK 24.28m |
| Other Expenses | DKK 74.29m |
| Earnings | -DKK 50.01m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 71.76% |
| Net Profit Margin | -147.84% |
| Debt/Equity Ratio | 0% |
How did 2P4 perform over the long term?
See historical performance and comparison